glp-1 appetite for Weight Loss and Diabetes Neurobiological Mechanisms and Therapeutic Potential

They reflect your body's adjustment to changes in digestion and appetite signaling

The latter is commonly defined as a composite of cardiovascular mortality, non-fatal MI, and non-fatal stroke (i.e., 3-point MACE), which sometimes also involves uAP (i.e., 4-point MACE)

Most insurance plans cover GLP-1 medications only when prescribed for diabetes or, in some cases, obesity with specific BMI criteria

27 The mean eGFR was 62 ml/min/1.73 m, and 76% of patients had NYHA class II symptoms

Just like we have learnt to advise hypertensive or hyperlipidemic patients on a healthy lifestyle but start therapy immediately, we need to recognize that many obese patients have wrestled with this for a lifetime, have tried multiple lifestyle interventions already